Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin survival study (4S)

https://doi.org/10.1016/S0002-9149(99)80473-1Get rights and content

The Scandinavian Simvastatin Survival Study (4S) was designed to evaluate the effects of cholesterol reduction with simvastatin on mortality and morbidity in patients with coronary artery disease (CAD). A total of 4,444 patients with angina pectoris or previous myocardial infarction and serum cholesterol levels of 213–310 mg/dl (5.5–8.0 mmol/liter) while treated with a lipid-lowering diet were randomly assigned to double-blind treatment with simvastatin or placebo. Over the 5.4 years of median follow-up, simvastatin produced changes in total cholesterol, low density lipoprotein (LDL) cholesterol, and high density lipoprotein (HDL) cholesterol of −25%, −35%, and +8%, respectively, with minimal adverse effects. A total of 256 patients (12%) in the placebo group died compared with 182 (8%) in the simvastatin group, a risk reduction of 30% (p = 0.0003) attributable to a 42% reduction in the risk of coronary death. Noncardiovascular causes accounted for 49 and 46 deaths in the placebo and simvastatin groups, respectively. Major coronary events were experienced by 622 patients (28%) in the placebo group and 431 patients (19%) in the simvastatin group, corresponding to a risk reduction of 34% (p <0.00001 ). This risk was also significantly reduced in subgroups consisting of women and patients of both sexes aged ≥60 years. Other benefits of treatment included a 37% reduction (p < 0.00001) in the risk of undergoing myocardial revascularization procedures. Simvastatin was beneficial regardless of whether patients had a history of myocardial infarction or whether they were smokers or had hypertension. Although only 202 patients had diabetes at randomization, a significant reduction in major coronary events was noted in this group (p = 0.002). The beneficial effect of simvastatin was also found to be independent of concomitant therapy with aspirin, β blockers, or calcium antagonists and was consistent across the whole range of baseline LDL cholesterol levels. This study shows that long-term treatment with simvastatin is safe and improves survival in CAD patients.

References (22)

  • IllingworthDR et al.

    Defined daily doses in relation to hypolipidaemic efficacy of lovastatin pravastatin and simvastatin

    Lancet

    (1994)
  • SacksFM et al.

    Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events Trial (CARE)

    Am J Cardiol

    (1991)
  • Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

    JAMA

    (1993)
  • PyöräläK et al.

    Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology European Atherosclerosis Society and European Society of Hypertension

    Eur Heart J

    (1994)
  • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

    Lancet

    (1994)
  • RossouwJE et al.

    The value of lowering cholesterol after myocardial infarction

    N Engl J Med

    (1990)
  • LawMR et al.

    By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

    Br Med J

    (1994)
  • GouldAL et al.

    Cholesterol reduction yields clinical benefit: a new look at old data

    Circulation

    (1995)
  • Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini GBJ. Reduction in cardiovascular...
  • ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction

    Lancet

    (1995)
  • EggerM et al.

    Misleading meta-analysis. Lessons from “an effective safe, simple” intervention that wasn't

    Br Med J

    (1995)
  • Cited by (153)

    • Sphingolipids and HDL Metabolism

      2014, The HDL Handbook: Biological Functions and Clinical Implications: Second Edition
    • Diabetes mellitus and peripheral vascular disease: Diagnosis and management

      2014, Clinics in Podiatric Medicine and Surgery
      Citation Excerpt :

      Likewise, no specific trials exist looking at patients with PAD for cholesterol-lowering therapy but several large studies with large PAD subgroups support certain cholesterol goals. The Scandinavian Simvastatin Survival Study noted reduction in cholesterol levels reduced the risk of new or progressive claudication.33 The Collaborative Atorvastatin Diabetes Study (CARDS) examined statins in patients solely with type 2 DM, and demonstrated a significant reduction in cardiovascular events irrespective of baseline low-density lipoprotein (LDL) level.34

    • Reporting of dietary control frameworks in studies on simvastatin efficacy

      2010, Clinical Nutrition
      Citation Excerpt :

      In addition, specific (and general) information on dietary data collection methods, dietary analysis outcomes or procedures to assure dietary adherence were generally not reported. In most of the studies,21,22,24,25,28,31–34 various dietary advice was provided for a pre-entry period to identify subjects with cholesterol levels consistent with the study inclusion protocols, and therefore was not included in the published analyses. The 4S study21,24,25,31–34 included a vague statement about dietary advice on lipid lowering being made according to the “European Atherosclerosis Society” prior to drug treatment, but provided little information on how this information was conveyed to patients and mechanisms to determine if indeed such recommendations were adopted and adhered to by patients.

    • Diabetes and Cardiovascular Disease Prevention in Older Adults

      2009, Clinics in Geriatric Medicine
      Citation Excerpt :

      However, the trial was terminated prematurely due to findings in the larger population sample, thereby underpowering the older adult subgroup analysis. Several trials have investigated statins for the secondary prevention of cardiovascular disease in adults with diabetes.36–60 In general, these trials demonstrated a beneficial effect of statins on lipid profiles and a reduction in cardiovascular events.

    View all citing articles on Scopus
    View full text